Literature DB >> 17374318

Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc.

Muba Taher1, Parbeer Grewal, Beth Gunn, Katia Tonkin, Gilles Lauzon.   

Abstract

BACKGROUND: Bazex syndrome (acrokeratosis paraneoplastica) is a rare paraneoplastic syndrome that usually occurs in males over 40 years old and is particularly associated with squamous cell carcinoma of the upper aerodigestive tract and adenopathy above the diaphragm.
OBJECTIVE: The objectives of our article are (1) to describe a unique case of acrokeratosis paraneoplastica and (2) to review the current literature regarding skin findings, commonly associated neoplasms, and treatment options relative to this condition. PATIENT: We describe a 68-year-old female with lobular breast carcinoma, complicated by local and distant recurrences, who presented with a 1-year history of prominent acral skin and nail changes.
RESULTS: Our patient's clinical skin findings improved significantly following treatment and partial remission of her underlying malignancy.
CONCLUSIONS: Our patient represents one of few females described with this syndrome, which is especially rare in association with lobular breast carcinoma. Further, the patient's presentation is unique as she was discovered to demonstrate laboratory findings consistent with coexistent porphyria cutanea tarda and relative zinc deficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374318     DOI: 10.2310/7750.2007.00015

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  2 in total

Review 1.  A Review of Nail Changes in Acrokeratosis Paraneoplastica (Bazex Syndrome).

Authors:  Bipasha Roy; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2021-03-02

2.  Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report.

Authors:  Aline Hempen; Eleftherios P Samartzis; Jivko Kamarachev; Daniel Fink; Konstantin J Dedes
Journal:  BMC Cancer       Date:  2015-07-08       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.